{"id":"W2017235356","doi":"10.1038/ki.2014.423","title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","year":2015,"lang":"en","type":"article","venue":"Kidney International","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":415,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Advancing Translational Sciences","keywords":"Eculizumab; Medicine; Thrombotic microangiopathy; Atypical hemolytic uremic syndrome; Internal medicine; Renal function; Gastroenterology; Surrogate endpoint; Kidney disease; Clinical trial; Alternative complement pathway; Phases of clinical research; Complement system; Immunology; Disease; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007794511,0.001359565,0.002930307,0.0005319696,0.0006428295,0.001542735,0.0008660152,0.002502286,0.002651803],"category_scores_gemma":[0.003559881,0.0004563052,0.002194956,0.000412736,0.0004833719,0.001509769,0.0005793367,0.003447192,0.0005588974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007910579,"about_ca_system_score_gemma":0.0008224616,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003727255,"about_ca_topic_score_gemma":0.0007798921,"domain_scores_codex":[0.9982923,0.000847745,0.0001572848,0.000174642,0.0002291448,0.0002989516],"domain_scores_gemma":[0.9972993,0.0007409852,0.0005502765,0.0002316646,0.000374271,0.0008034962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6737277,0.02881007,0.01665185,0.001684914,0.003734694,0.0005831012,0.00042089,0.002812546,0.03029496,0.0004018983,0.00693632,0.233941],"study_design_scores_gemma":[0.4531653,0.4633867,0.06207336,0.0003257673,0.001690578,0.0008578587,0.00007965985,0.002052706,0.005952903,0.0004331694,0.009878826,0.0001030292],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731662,0.01855708,0.001156204,0.0009198514,0.0002654926,0.00186545,0.001507912,0.0001233815,0.00243839],"genre_scores_gemma":[0.9802711,0.005886679,0.001497193,0.0023169,0.0004278121,0.003317338,0.004084828,0.00003166878,0.002166477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007794511,"threshold_uncertainty_score":0.0412218,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04876517728652985,"score_gpt":0.3404567817363381,"score_spread":0.2916916044498082,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}